Chipscreen(SH:688321) Ge Long Hui A P P·2026-02-26 10:16Core Viewpoint - Microchip Biotech (688321.SH) reported significant growth in its 2025 annual performance, with a notable increase in revenue and net profit, driven by successful commercialization of its products and strategic partnerships [1] Financial Performance - The company's annual operating revenue for 2025 reached 909.54 million yuan [1] - Total profit amounted to 50.84 million yuan [1] - Net profit attributable to shareholders was 51.08 million yuan [1] - Net profit after deducting non-recurring gains and losses was 38.36 million yuan [1] - Earnings per share stood at 0.1252 yuan [1] Product Performance - Sales revenue of the product Siglecatin Sodium increased by approximately 122% year-on-year, attributed to its unique clinical value in "diabetes liver co-management" and enhanced commercialization efforts through self-operated, strategic partnerships, and new retail channels [1] - Sales revenue of the product Sidabamine grew by around 16% year-on-year, supported by its recognition in the market and inclusion of a new indication for diffuse large B-cell lymphoma in the National Medical Insurance Directory in January 2025, followed by regular Class B management in December 2025 [1]